Janus kinase 3

Protein · UniProt

Tyrosine-protein kinase JAK3

Gene

JAK3

Organism

Homo sapiens (Human)

Length

1,124 aa

Molecular mass

125,099 Da

Evidence

1: Evidence at protein level

Non-receptor tyrosine kinase involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking si…

• Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.International journal of molecular sciences · 2024
• Janus kinase-1 and 3 in ankylosing spondylitis.Journal of the Formosan Medical Association = Taiwan yi zhi · 2019
• Janus kinase-3 (JAK3) inhibition: a novel immunosuppressive option for allogeneic transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2004
• Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.Archivum immunologiae et therapiae experimentalis · 2004
• Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.Current pharmaceutical design · 2004

via PubMed

• PHASE2/PHASE3TERMINATED
  GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host DiseaseIncyte Corporation · NCT03584516
• PHASE3COMPLETED
  Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic DermatitisPfizer · NCT03422822
• PHASE1/PHASE2RECRUITING
  Retifanlimab and Ruxolitinib In Solid MalignanciesUniversity of California, San Diego · NCT07219576
• PHASE2/PHASE3TERMINATED
  Efficacy & Safety of TD-1473 in Ulcerative ColitisTheravance Biopharma · NCT03758443
• ENROLLING_BY_INVITATION
  Effective Treatment of Jak1/3 Inhibitor in Blau SyndromeTongji Hospital · NCT06688838
• PHASE2/PHASE3TERMINATED
  TD-1473 Long-Term Safety (LTS) Ulcerative Colitis (UC) StudyTheravance Biopharma · NCT03920254

via ClinicalTrials.gov

Wikidata facts

Instance of

protein

Image

Protein JAK3 PDB 1yvj.png

via Wikidata · CC0